Document is current
Any future updates will be listed below
-
Authors
Nakashoji, Ayako
Bhattacharya, Atrayee
Ozawa, Hiroki
Haratake, Naoki
Shigeta, Keisuke
Fushimi, Atsushi
Yamashita, Nami
Matsui, Akira
Kure, Shoko
Kameyama, Tomoe
Takeuchi, Makoto
Fukuda, Kazumasa
Yokoe, Takamichi https://orcid.org/0000-0001-7068-7117
Nagayama, Aiko
Hayahsida, Tetsu
Kitagawa, Yuko
Liu, Renyan
Giordano, Antonio https://orcid.org/0000-0002-7760-9717
Jeselsohn, Rinath https://orcid.org/0000-0001-7996-7529
Shapiro, Geoffrey I. https://orcid.org/0000-0002-3331-4095
Kufe, Donald https://orcid.org/0000-0001-5743-8888
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA97098)
Saverin Breast Cancer Research Fund is a fund of The Dana-Farber Cancer Institute aimed at extending the lives of metastatic breast cancer patients.
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 27 March 2025
First Online: 26 April 2025
Competing interests
: D.K. has equity interests in Genus Oncology and is a paid consultant to CanBas. R.J. declares research funds (to institution) from Pfizer and Lilly and advisory/consultant role for Lilly, Pfizer, GE Health, and Carrick Therapeutics. G.I.S. reports grants and personal fees from Merck KGaA/EMD Serono; grants from Tango Therapeutics, Bristol Myers Squibb, Pfizer, Eli Lilly, Merck & Co, and Artios; and personal fees Circle Pharmaceuticals, Schrodinger, and Concarlo Therapeutics. The other authors declared no potential competing interests.
